The First Report of the Prevalence of COVID-19 in Chronic Myelogenous Leukemia Patients in the Core Epidemic Area of China: A Multicentre, Cross-Sectional Survey
暂无分享,去创建一个
L. Meng | Youlin Zhao | Zhuangzhi Yang | Hong-xiang Wang | Bi-xiao Chen | Jie Du | Yapei Wang | X. Zuo | Qing Li | Y. You | Xiaojian Zhu | Weiming Li | Hong Han | Renying Ge | Qihuan Liu | C. Wan | Y. Bao | H. Xiang | Hong-bo Ren | Zhiping Huang | Jun Huang | Guolin Yuan | Zhichao Chen | Zhe Zhao | Xin-hua Zhang | Dan-Yu Wang | Jingming Guo | Yun-Hui Wei | Hui Cheng | Da-lin Zhang | Dao-zi Jiang | Shiming Chen | You-shan Zhang | Qing Wu | Yun-hui Wei
[1] C. Schiffer,et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia , 2020, Leukemia.
[2] Li Zhang,et al. Risk of COVID-19 for patients with cancer , 2020, The Lancet Oncology.
[3] Huahao Shen,et al. Risk of COVID-19 for patients with cancer , 2020, The Lancet Oncology.
[4] Novel Coronavirus Pneumonia Emergency Response Epidemiol Team. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. , 2020, Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi.
[5] Ruchong Chen,et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China , 2020, The Lancet Oncology.
[6] Bikesh Shrestha,et al. The first 2019 novel coronavirus case in Nepal , 2020, The Lancet Infectious Diseases.
[7] Moran Ki,et al. Epidemiologic characteristics of early cases with 2019 novel coronavirus (2019-nCoV) disease in Korea , 2020, Epidemiology and health.
[8] Liz J Walker. 2019-nCoV acute respiratory disease, Australia - Epidemiology Report 1 (Reporting week 26 January – 1 February 2020) , 2020 .
[9] W. Silverstein,et al. First imported case of 2019 novel coronavirus in Canada, presenting as mild pneumonia , 2020, The Lancet.
[10] Hiroshi Nishiura,et al. The Rate of Underascertainment of Novel Coronavirus (2019-nCoV) Infection: Estimation Using Japanese Passengers Data on Evacuation Flights , 2020, Journal of clinical medicine.
[11] S. Lindstrom,et al. First Case of 2019 Novel Coronavirus in the United States , 2020, The New England journal of medicine.
[12] Ting Yu,et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.
[13] Q. Pham,et al. Importation and Human-to-Human Transmission of a Novel Coronavirus in Vietnam , 2020, The New England journal of medicine.
[14] Pyoeng Gyun Choe,et al. The First Case of 2019 Novel Coronavirus Pneumonia Imported into Korea from Wuhan, China: Implication for Infection Prevention and Control Measures , 2020, Journal of Korean medical science.
[15] H. Ureshino,et al. Role of cancer immunology in chronic myelogenous leukemia. , 2019, Leukemia research.
[16] K. Iwaisako,et al. Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells , 2019, The Journal of experimental medicine.
[17] M. Plana,et al. Immunomodulatory Activity of Tyrosine Kinase Inhibitors to Elicit Cytotoxicity Against Cancer and Viral Infection , 2019, Front. Pharmacol..
[18] J. Cayuela,et al. The rising prevalence of chronic myeloid leukemia in France. , 2018, Leukemia research.
[19] M. Frieman,et al. Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors , 2018, bioRxiv.
[20] M. Frieman,et al. Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion , 2016, Journal of Virology.
[21] M. Höglund,et al. Epidemiology of chronic myeloid leukaemia: an update , 2015, Annals of Hematology.
[22] Julie Dyall,et al. Repurposing of Clinically Developed Drugs for Treatment of Middle East Respiratory Syndrome Coronavirus Infection , 2014, Antimicrobial Agents and Chemotherapy.
[23] U. Olsson‐Strömberg,et al. Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry. , 2013, Blood.
[24] H. Kantarjian,et al. Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009 , 2013, Leukemia & lymphoma.
[25] Yi-Hsin Yang,et al. Estimation of CML incidence: disagreement between national cancer registry and health claims data system in Taiwan. , 2011, Leukemia research.
[26] S. Harrison,et al. The Scotland Leukaemia Registry Audit of Incidence, Diagnosis and Clinical Management of New Patients with Chronic Myeloid Leukaemia in 1999 and 2000 , 2004, Scottish medical journal.